What is Evonetix?
Evonetix is pioneering a transformative approach to gene synthesis, focusing on the development of technology that enhances access to high-quality, gene-length DNA. By integrating advanced engineering with biological sciences, the company aims to provide researchers across healthcare, agriculture, and manufacturing with the tools necessary to drive innovation at scale. Their core value proposition lies in the ability to facilitate rapid, reliable DNA production, effectively establishing a gene foundry in every laboratory. This capability is essential for the advancement of personalized medicine and the broader engineering biology sector, where the demand for custom genetic material is growing exponentially. Evonetix is strategically positioned to address global challenges by lowering the barriers to entry for complex biological research.
How much funding has Evonetix raised?
Evonetix has raised a total of $66.3M across 2 funding rounds:
Series A
$12.3M
Series B
$54M
Series A (2018): $12.3M with participation from Morningside Group, DCVC Management, Molten, and Providence Investment Advisors
Series B (2023): $54M led by Rising Tide Fund, Providence Investment Company, Morningside Group, Foresite Capital, Cambridge Consultants Ltd, Data Collective, Molten, and Civilization Ventures
Key Investors in Evonetix
Rising Tide Fund
A Silicon Valley-based investment firm with a global footprint, specializing in supporting exceptional entrepreneurs from the early stages of venture creation through to realization.
Foresite Capital
A multi-stage investment firm focused on transforming healthcare and life sciences by utilizing data science-driven approaches to fund breakthrough biotechnology companies.
Data Collective
A mission-driven organization dedicated to building and supporting technology that improves data accessibility and knowledge sharing for the public good.
What's next for Evonetix?
With the successful closure of its latest funding round, Evonetix is poised to enter a critical phase of operational scaling and market expansion. The company's strategic roadmap focuses on refining its synthesis platform to meet the increasing demand for high-throughput, high-fidelity DNA sequences. By leveraging this major strategic investment, Evonetix will likely prioritize the expansion of its technical team and the enhancement of its manufacturing infrastructure to support global research initiatives. Furthermore, the company is expected to deepen its partnerships within the life sciences ecosystem, ensuring that its technology remains at the forefront of the engineering biology revolution. As the industry shifts toward more personalized therapeutic solutions, Evonetix's ability to provide rapid, scalable DNA synthesis will be a key differentiator in maintaining its competitive advantage.
See full Evonetix company page
